Connect Biopharmaceuticals snags $55 mln Series B
China-based Connect Biopharmaceuticals, a clinical-stage company that focuses on treating autoimmune diseases and inflammation, has closed $55 million in Series B financing. Advantech Capital led the round with participation from return backers Qiming Venture Partners, Northern Light Venture Capital and Cowin Venture. CEC Capital was financial adviser on the transaction.
3 January 2019•1 min read
